Historic MS Trial Clearance

Quantum BioPharma Secures FDA Clearance to Launch Historic Lucid-MS Trials

Quantum BioPharma Ltd. (NASDAQ: QNTM) has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class candidate designed to shield and potentially rebuild the myelin sheath itself. This would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS. This milestone has already attracted a fresh buy rating from Wall Street analysts. Quantum BioPharmaceutical company is focused on developing innovative assets and biotech solutions for the treatment of neurodegenerative and metabolic disorders and alcohol misuse disorders. The company also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Topics